Desonide (Synonyms: Budesonide acetonide) |
カタログ番号GC15690
One-Click Copy Product Info
|
デソニドは、皮膚病に局所的に使用される非フッ素化コルチコステロイド抗炎症剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 638-94-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.Target: Glucocorticoid ReceptorDesonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive dermatoses [1]. Desonide induced significant colorimetric improvement compared with placebo. A good to excellent response was achieved in 30% for desonide, and 6% for placebo. Decreased pigmentation in the desonide-treated axillae was associated with recovery of disruption at the basal membrane. Desonide showed depigmenting properties in women with axillary hyperpigmentation [2]. Given the favorable safety profile of all other desonide preparations and their utility as a low potency corticosteroid, desonide foam promises to be a useful addition to the armamentarium, when other desonide vehicles might be less acceptable [3].
References:
[1]. Kahanek, N., C. Gelbard, and A. Hebert, Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs, 2008. 17(7): p. 1097-104.
[2]. Castanedo-Cazares, J.P., et al., Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol, 2013. 6: p. 29-36.
[3]. Parish, D. and N. Scheinfeld, Desonide foam: a review. Drugs Today (Barc), 2008. 44(1): p. 55-62.
| Cas No. | 638-94-8 | SDF | |
| 同義語 | Budesonide acetonide | ||
| Chemical Name | (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one | ||
| Canonical SMILES | O=C(C([H])([H])O[H])[C@@]12OC(C([H])([H])[H])(C([H])([H])[H])O[C@]1([H])C([H])([H])[C@]([C@@](C([H])([H])C3([H])[H])([H])[C@@]4([H])[C@@](C([H])([H])[H])(C([H])=C5[H])C3=C([H])C5=O)([H])[C@]2(C([H])([H])[H])C([H])([H])[C@]4([H])O[H] | ||
| Formula | C24H32O6 | M.Wt | 416.51 |
| 溶解度 | ≥ 20.85mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4009 mL | 12.0045 mL | 24.009 mL |
| 5 mM | 480.2 μL | 2.4009 mL | 4.8018 mL |
| 10 mM | 240.1 μL | 1.2005 mL | 2.4009 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)